Skip to main content
. Author manuscript; available in PMC: 2009 Sep 29.
Published in final edited form as: Am J Obstet Gynecol. 2007 Oct;197(4):396.e1–396.e9. doi: 10.1016/j.ajog.2007.07.020

Figure 7.

Figure 7

The difference in fetal recipient survival is more pronounced among recipients in stages III and IV that were treated by AR (63%) versus SFLP (12.5%, p < 0.03). Despite these differences in fetal recipient survival, there is no difference in survival at 30 days because 7/20 recipients in the AR arm met criteria for treatment failure (in which 6 of the 7 were neonatal deaths) while 0/20 in the SFLP arm did so.